| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1021 | 2019 |
| Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification B Bulik-Sullivan, J Busby, CD Palmer, MJ Davis, T Murphy, A Clark, ... Nature biotechnology 37 (1), 55-63, 2019 | 259 | 2019 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 184 | 2018 |
| Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer C Buttigliero, M Tucci, V Bertaglia, F Vignani, P Bironzo, M Di Maio, ... Cancer treatment reviews 41 (10), 884-892, 2015 | 179 | 2015 |
| Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study ML Iacono, V Monica, L Righi, F Grosso, R Libener, S Vatrano, P Bironzo, ... Journal of thoracic oncology 10 (3), 492-499, 2015 | 176 | 2015 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 95 | 2021 |
| A review of guidelines for lung cancer P Bironzo, M Di Maio Journal of Thoracic Disease 10 (Suppl 13), S1556, 2018 | 85 | 2018 |
| Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 L Marandino, A La Salvia, C Sonetto, E De Luca, D Pignataro, C Zichi, ... Annals of oncology 29 (12), 2288-2295, 2018 | 82 | 2018 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity A Inno, G Metro, P Bironzo, AM Grimaldi, E Grego, V Di Nunno, V Picasso, ... Tumori Journal 103 (5), 405-421, 2017 | 66 | 2017 |
| DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients M Schena, S Guarrera, L Buffoni, A Salvadori, F Voglino, A Allione, ... DNA repair 11 (4), 374-380, 2012 | 51 | 2012 |
| Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma IC Salaroglio, J Kopecka, F Napoli, M Pradotto, F Maletta, L Costardi, ... Journal of Thoracic Oncology 14 (8), 1458-1471, 2019 | 50 | 2019 |
| Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes M Betti, A Aspesi, D Ferrante, M Sculco, L Righi, D Mirabelli, F Napoli, ... Genes, Chromosomes and Cancer 57 (11), 573-583, 2018 | 50 | 2018 |
| Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment C Riganti, MF Lingua, IC Salaroglio, C Falcomatà, L Righi, D Morena, ... Oncoimmunology 7 (3), e1398874, 2018 | 45 | 2018 |
| Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ... Cancer discovery 13 (7), 1556-1571, 2023 | 43 | 2023 |
| Addressing the unmet need in lung cancer: the potential of immuno-oncology GV Scagliotti, P Bironzo, JF Vansteenkiste Cancer treatment reviews 41 (6), 465-475, 2015 | 43 | 2015 |
| Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone A Pia, F Vignani, G Attard, M Tucci, P Bironzo, G Scagliotti, W Arlt, ... Cancer treatment reviews 39 (8), 966-973, 2013 | 42 | 2013 |
| Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018 ML Reale, E De Luca, P Lombardi, L Marandino, C Zichi, D Pignataro, ... Lung Cancer 139, 47-54, 2020 | 39 | 2020 |
| Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 V Milosevic, J Kopecka, IC Salaroglio, R Libener, F Napoli, S Izzo, ... International journal of cancer 146 (1), 192-207, 2020 | 39 | 2020 |
| Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma T Villanova, I Gesmundo, V Audrito, N Vitale, F Silvagno, C Musuraca, ... Proceedings of the National Academy of Sciences 116 (6), 2226-2231, 2019 | 36 | 2019 |
